ArticleOphthalmology and therapy2025
The Use of a Viscous Cysteamine Eyedrop in a Belgian Cohort: Early 3-Year Results.
Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CystadropsOphthalmology and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWith the life expectancy of patients with cystinosis increasing (ORPHA213), the corneal burden and the objective assessment of corneal crystal deposition have become increasingly important. Previous research highlights the disadvantages of hospital-prepared cysteamine solutions (HPCS), including limited efficacy, which can lead to visual decline. Cystadrops
methodsA total of 14 patients with cystinosis and corneal involvement are being followed in the multidisciplinary cystinosis clinic of the University Hospital of Leuven. Data retrieved between September 2014 and March 2023 were analyzed. All patients were initially treated with HPCS before switching to Cystadrops
resultsOCT mean crystal depth was 83% of total corneal thickness. The mean corneal density was 28.9 grayscale units. We found a positive trend (F = 0.20, p = 0.65) in corneal densitometry despite the use of HPCS, with a decreasing trend (F = 3.30, p = 0.08) after switching to Cystadrops
conclusionsThis study underscores previous research, demonstrating HPCS' limited effectiveness in reducing corneal crystal deposition due to unachievable dosing frequencies and poor stability. Our data highlights the effectiveness of Cystadrops
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.